Q-omics provides the consensus-scored EDDM3A profile across patient tissues and cancer cell-line models. EDDM3A expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, EDDM3A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, EDDM3A RNA expression shows 6,954 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, KIRC, and TGCT as cancer lineages where EDDM3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EDDM3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EDDM3A survival associations across molecular data types. EDDM3A RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EDDM3A RNA expression–survival associations across cancer types. High EDDM3A expression shows unfavorable associations in STAD, LUSC, KICH, LGG and UCEC, but favorable associations in KIRP. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for EDDM3A RNA expression.
This table summarizes EDDM3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EDDM3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EDDM3A shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in HNSC, BLCA and LUAD. The KIRC box plot shows higher EDDM3A RNA expression in normal versus tumor tissue (log2 FC = −1.333, t-test p < 0.001).
This table shows molecular features associated with EDDM3A in patient tissues and cancer cell lines. In patient samples, EDDM3A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EDDM3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
